deltatrials
Completed PHASE1/PHASE2 NCT00002508

Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors

INTENSIVE CHEMOTHERAPY FOR RELAPSED OR REFRACTORY GERM CELL TUMORS EMPLOYING HIGH-DOSE CARBOPLATIN, ETOPOSIDE, AND THIOTEPA WITH AUTOLOGOUS BONE MARROW RESCUE FOR PATIENTS 15 TO 60 YEARS OF AGE

Sponsor: Fox Chase Cancer Center

Conditions Extragonadal Germ Cell Tumor Ovarian Cancer Testicular Germ Cell Tumor
Interventions autologous bone marrow transplantation carboplatin etoposide peripheral blood stem cell transplantation
Updated 5 times since 2017 Last updated: Sep 30, 2010 Started: Nov 30, 1990 Primary completion: Sep 30, 2001 Completion: Sep 30, 2001

This PHASE1/PHASE2 trial investigates Extragonadal Germ Cell Tumor and Ovarian Cancer and is currently completed. Fox Chase Cancer Center leads this study, which shows 5 recorded versions since 1990 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Nov 1990

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fox Chase Cancer Center
  • Temple University
Data source: Temple University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Philadelphia, United States